Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
VERV | US
0.20
4.17%
Healthcare
Biotechnology
30/06/2024
04/10/2024
5.00
4.77
5.02
4.73
Verve Therapeutics Inc. a genetic medicines company engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101 a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia Inc. and changed its name to Verve Therapeutics Inc. in January 2019. Verve Therapeutics Inc. was incorporated in 2018 and is headquartered in Cambridge Massachusetts.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
46.1%1 month
50.2%3 months
81.6%6 months
68.0%-
-
0.77
0.13
0.10
-0.40
1.97
-
-215.68M
423.12M
423.12M
-
-879.24
-
219.70
-38.10
9.74
22.39
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.77
Range1M
1.76
Range3M
3.65
Rel. volume
0.77
Price X volume
4.98M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Ginkgo Bioworks Holdings Inc. | DNA | Biotechnology | 8.33 | 462.94M | 8.04% | n/a | 54.29% |
EyePoint Pharmaceuticals Inc | EYPT | Biotechnology | 8.63 | 461.86M | 5.12% | n/a | 10.20% |
Quanterix Corporation | QTRX | Biotechnology | 11.9 | 456.71M | -4.80% | n/a | 11.75% |
Mind Medicine (MindMed) Inc. Subordinate Voting Shares | MNMD | Biotechnology | 5.57 | 456.67M | 0.36% | n/a | 12.00% |
Alector Inc | ALEC | Biotechnology | 4.62 | 449.62M | 2.67% | n/a | 23.98% |
Xeris Pharmaceuticals Inc | XERS | Biotechnology | 2.98 | 444.02M | 2.41% | n/a | -1398.96% |
Absci Corporation Common Stock | ABSI | Biotechnology | 3.88 | 440.60M | 2.11% | n/a | 6.02% |
Foghorn Therapeutics Inc | FHTX | Biotechnology | 7.83 | 433.22M | -6.00% | n/a | -285.69% |
Esperion Therapeutics Inc | ESPR | Biotechnology | 2.16 | 423.85M | 18.68% | n/a | -161.71% |
Taysha Gene Therapies Inc | TSHA | Biotechnology | 2.01 | 417.91M | -1.95% | n/a | 53.02% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.63 | 366.05M | 0.00% | 47.92 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 21.28 | 334.47M | -4.23% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.47 | 328.78M | 0.21% | 13.24 | 0.00% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.64 | 292.95M | -0.56% | 35.53 | 26.82% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14 | 87.66M | -1.27% | 14.62 | 7.10% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 7.64 | 83.40M | -1.93% | n/a | 58.43% |
Urban One Inc | UONEK | Broadcasting - Radio | 1.02 | 57.65M | -4.67% | n/a | 268.43% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.40 | 0.76 | Cheaper |
Ent. to Revenue | 1.97 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 0.77 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 81.64 | 74.67 | Par |
Debt to Equity | 0.13 | -1.82 | Expensive |
Debt to Assets | 0.10 | 0.26 | Cheaper |
Market Cap | 423.12M | 3.73B | Emerging |